Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.8K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.8K
Cancer Therapies02:49

Cancer Therapies

9.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

3.3K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Haematologica·2026
Same author

Correction: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion.

Frontiers in oncology·2026
Same author

Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia Using Optical Genome Mapping, Karyotyping, and Next-Generation Sequencing.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion.

Frontiers in oncology·2026
Same author

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

Cancer·2025
Same author

Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia.

American journal of hematology·2025
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
Same journal

Association between interleukin-10 (IL-10) genetic polymorphisms and non-hodgkin lymphoma: a systematic review and meta-analysis.

Leukemia & lymphoma·2026
Same journal

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Leukemia & lymphoma·2026
Same journal

Efficacy of allogeneic haematopoietic stem cell transplantation in acute myeloid leukemia with myelodysplasia-related genetics.

Leukemia & lymphoma·2026
Same journal

Shared decision-making, treatment priorities and communication gaps in chronic lymphocytic leukemia: an Israeli national survey.

Leukemia & lymphoma·2026
See all related articles

Related Experiment Video

Updated: Jan 19, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

581

CPX-351 (vyxeos) in AML.

Mansour Alfayez1, Hagop Kantarjian1, Tapan Kadia1

  • 1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Leukemia & Lymphoma
|September 25, 2019
PubMed
Summary
This summary is machine-generated.

CPX-351 (vyxeos), a novel liposomal chemotherapy, significantly improved overall survival (OS) in newly diagnosed acute myeloid leukemia (AML) patients compared to the standard 7+3 regimen. This finding supports CPX-351 as a new standard for AML treatment.

Keywords:
AML in elderlyAML-MRCCPX-351VyxeossAMLt-AML

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

641
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

Related Experiment Videos

Last Updated: Jan 19, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

581
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

641
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • The standard induction chemotherapy for acute myeloid leukemia (AML) has been the cytarabine plus anthracycline (7+3) regimen for decades.
  • CPX-351 (vyxeos), a liposomal formulation of cytarabine and daunorubicin, was approved in August 2017 for specific AML subgroups.
  • This approval marked the first targeted treatment for adults with newly diagnosed AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML).

Purpose of the Study:

  • To review preclinical and clinical data on CPX-351.
  • To discuss the efficacy and safety of CPX-351 compared to the standard 7+3 regimen.
  • To explore limitations and future directions for CPX-351 in AML treatment.

Main Methods:

  • A multicenter, randomized, open-label, phase III study compared CPX-351 to the 7+3 regimen.
  • The study included patients aged 60-75 years with newly diagnosed AML-MRC or t-AML.
  • Outcomes assessed included overall survival (OS).

Main Results:

  • CPX-351 demonstrated a higher median OS than the 7+3 regimen (9.56 vs. 5.95 months).
  • The hazard ratio (HR) for OS was 0.69 (95% CI: 0.52 to 0.90, p=0.005), favoring CPX-351.
  • This indicates a statistically significant improvement in survival for patients treated with CPX-351.

Conclusions:

  • CPX-351 represents a significant advancement in the treatment of newly diagnosed AML-MRC and t-AML.
  • The improved OS observed in the phase III study supports the use of CPX-351 over the traditional 7+3 regimen for these patient populations.
  • Further research may elucidate optimal use and long-term outcomes with CPX-351.